BioInvent International has secured FDA Fast Track Designation for BI-1808 in the treatment of relapsed or refractory mycosis fungoides and Sézary syndrome, two subtypes of cutaneous T-cell lymphoma.
The renal cancer clinical trial pipeline is robust, with over 70 companies developing more than 75 therapies, including novel immunotherapies and targeted agents.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.